Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
$0.82
-0.7%
$0.85
$0.55
$1.66
$107.21M0.9762,238 shs589,597 shs
Avinger, Inc. stock logo
AVGR
Avinger
$0.47
$0.47
$0.36
$1.93
$1.57M1.291.33 million shsN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.08
$0.09
$0.06
$0.29
$876K0.517,844 shs22,457 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$0.31
-10.8%
$0.44
$0.16
$2.31
$17.74M0.699.99 million shs11.61 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-5.63%+3.75%+5.80%+27.50%-30.25%
Avinger, Inc. stock logo
AVGR
Avinger
0.00%0.00%0.00%0.00%-74.52%
Dynatronics Co. stock logo
DYNT
Dynatronics
+7.84%+8.13%+1.85%-22.17%-68.87%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
+10.38%+88.71%+22.94%-65.90%-76.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
2.3435 of 5 stars
3.71.00.00.03.81.70.0
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/AN/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
1.8745 of 5 stars
3.32.00.00.02.90.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
3.33
Buy$6.17648.20% Upside
Avinger, Inc. stock logo
AVGR
Avinger
0.00
N/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00
N/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.50
Moderate Buy$10.833,393.50% Upside

Current Analyst Ratings Breakdown

Latest AVGR, DYNT, ATOS, and PSTV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.50 ➝ $3.00
6/25/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$9.00
6/6/2025
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.25 ➝ $7.50
6/5/2025
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$4.00
6/5/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $20.50
5/5/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/5/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/21/2025
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $7.25
4/21/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$19.00 ➝ $20.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/AN/AN/AN/A$0.57 per shareN/A
Avinger, Inc. stock logo
AVGR
Avinger
$7.65M0.21N/AN/A($4.53) per share-0.10
Dynatronics Co. stock logo
DYNT
Dynatronics
$33.60M0.03N/AN/A$0.57 per share0.14
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$5.82M2.72N/AN/A($1.52) per share-0.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-$25.50M-$0.21N/AN/AN/AN/A-33.90%-31.53%8/11/2025 (Estimated)
Avinger, Inc. stock logo
AVGR
Avinger
-$18.32M-$11.06N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)
Dynatronics Co. stock logo
DYNT
Dynatronics
-$2.70M-$0.78N/AN/A-8.35%-41.81%-9.56%N/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$12.98M-$2.94N/AN/AN/A-520.90%N/A-202.73%8/13/2025 (Estimated)

Latest AVGR, DYNT, ATOS, and PSTV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.17-$0.56-$0.39-$1.19$1.11 million$1.06 million
5/13/2025Q1 2025
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-$0.06-$0.05+$0.01-$0.05N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/AN/AN/AN/AN/A
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/A
12.67
12.67
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
0.25
1.21
0.60
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
1.03
1.03

Institutional Ownership

CompanyInstitutional Ownership
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
12.74%
Avinger, Inc. stock logo
AVGR
Avinger
18.30%
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%

Insider Ownership

CompanyInsider Ownership
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
8.70%
Avinger, Inc. stock logo
AVGR
Avinger
42.80%
Dynatronics Co. stock logo
DYNT
Dynatronics
7.98%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
5.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
8129.17 million117.93 millionOptionable
Avinger, Inc. stock logo
AVGR
Avinger
703.31 million1.89 millionNot Optionable
Dynatronics Co. stock logo
DYNT
Dynatronics
20010.62 million8.11 millionNot Optionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2051.00 million48.20 millionNot Optionable

Recent News About These Companies

Plus (PSTV) Upgraded to Buy: Here's Why

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Atossa Genetics stock logo

Atossa Genetics NASDAQ:ATOS

$0.82 -0.01 (-0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$0.82 0.00 (-0.51%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Avinger stock logo

Avinger NASDAQ:AVGR

$0.47 0.00 (0.00%)
As of 06/30/2025

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.

Dynatronics stock logo

Dynatronics NASDAQ:DYNT

$0.08 0.00 (0.00%)
As of 01:39 PM Eastern

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

Plus Therapeutics stock logo

Plus Therapeutics NASDAQ:PSTV

$0.31 -0.04 (-10.84%)
Closing price 04:00 PM Eastern
Extended Trading
$0.32 +0.00 (+1.58%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.